Navigation Links
Helix BioPharma Announces $13.5 Million Private Placement
Date:9/3/2009

AURORA, Ontario, Sept. 4 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009.

Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase one common share of the Company at a price of $2.87 for up to three years after the closing date of the private placement. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

    For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                       Ian Stone
    Russo Partners LLC                        Russo Partners LLC
    Tel: (212) 845-4226                       Tel: (619) 814-3510
    robert.flamm@russopartnersllc.com         Fax: (619) 955-5318
    www.russopartnersllc.com                  ian.stone@russopartnersllc.com

This News R
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
2. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
3. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
4. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
5. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
6. Helix BioPharma to Present at the BioFinance 2009 Conference
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. Helix BioPharma Announces Q2 2009 Financial Results
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
11. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/26/2015)... -- On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury verdict ... excess of $10 million. The jury determined that Genewiz ... it improperly hired one or more of GenScript,s employees.  ... notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... MENLO PARK, Calif. , Feb. 26, 2015 /PRNewswire/ ... has released the latest version of the Governance ... organizations accomplish governance, risk and compliance (GRC) tasks across ... has also been updated to help customers better align ... Organizations of the Treadway Commission ) requirements. In response ...
(Date:2/26/2015)... The healthcare landscape is rapidly and radically changing. ... will host its 20 th Anniversary Medical Technologies ... to 10, at the Hilton San Diego Resort and Spa ... This event is a platform for global medical devices, diagnostics, ... and how to succeed in an uncertain future. ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... COATED PLATE ASSAYS , ... the counting of radioimmunoassays based on coated microtitration plates. The following method ... compare the standard immunoassay microtitration plates with those manufactured by PerkinElmer Life ... procedure is straightforward: , (1) Coat ...
... , ... Dpartement dImmunologie, Laboratoires Fournier S.A., France ... TGF- type I and type II receptors ... type II (TRII) tends to act as the primary receptor. In the ...
... L. Smith1, M.J. Price-Jones 1 , K.T. ... plc., Forest Farm, Whitchurch, Cardiff, CF4 7YT, Wales, UK, 2 PerkinElmer ... , INTRODUCTION ... a multi-detector instrument designed for liquid scintillation (LS) or luminescence detection of samples ...
Cached Biology Technology:Coated Plate Immunoassay on the MicroBeta - eg. TSH - IRMA 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 3Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 4Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 5Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 6Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 7Counting Cytostar-T scintillating microplates on the MicroBeta JET 2Counting Cytostar-T scintillating microplates on the MicroBeta JET 3Counting Cytostar-T scintillating microplates on the MicroBeta JET 4Counting Cytostar-T scintillating microplates on the MicroBeta JET 5
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Philadelphia, PA, May 2, 2012 Although the ... associated. Individuals with epilepsy are more likely to have ... risk factor for psychosis. It is not known whether ... of psychosis is a risk factor for epilepsy. ...
... Infants born to women who used the anti-HIV drug tenofovir ... not weigh less at birth and are not of shorter ... regimens that do not include tenofovir during pregnancy, according to ... However, at 1 year of age, children born to ...
... to sneak up on a huge dinosaur while it sleeps, crawl ... have felt like a needle going in but giant "flea-like" ... just that. And a few actually lived through the experience, ... these creatures, just announced in Current Biology, a professional ...
Cached Biology News:Evidence of familial vulnerability for epilepsy and psychosis 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 3Jurassic pain: Giant 'flea-like' insects plagued dinosaurs 165 million years ago 2
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... positively and negatively supercoiled DNA in presence of ... the effects of supercoiling on transcription in vitro ... , Determining the degree of supercoiling of naturally ... differ in length by only one base-pair ...
... Kit for Kilo-Sequencing is designed to aid ... into the multiple cloning sites (MCS) of ... or phagemid vectors (pUC18/19). The kit is ... the target DNA, thereby progressively moving the ...
Biology Products: